



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

# PRODUCT INFORMATION



## IDH1 R132H mutant (human recombinant)

Item No. 14132

### Overview and Properties

**Synonyms:** Isocitrate Dehydrogenase (NADP) Cytoplasmic  
**Source:** Active recombinant C-terminal histidine-tagged protein expressed in *E. coli*  
**Amino Acids:** 2-414 (full-length)  
**Uniprot No.:** O75874



Batch specific information can be found on the Certificate of Analysis or by contacting Technical Support

**Molecular Weight:** 47.9 kDa  
**Storage:** -80°C (as supplied); avoid freeze/thaw cycles by aliquoting protein  
**Stability:** As supplied, 6 months from the QC date provided on the Certificate of Analysis, when stored properly  
**Purity:** *batch specific* ( $\geq 95\%$  estimated by SDS-PAGE)  
**Supplied in:** 50 mM Tris-HCl, pH 7.5, containing 200 mM sodium chloride, 5 mM  $\beta$ -mercaptoethanol, and 10% glycerol

#### Protein

**Concentration:** *batch specific* mg/ml  
**Activity:** *batch specific* U/ml  
**Specific Activity:** *batch specific* U/mg  
**Unit Definition:** One unit is defined as the amount of enzyme required to convert 1 nmol of NADPH to NADP<sup>+</sup>, using 15 mM  $\alpha$ -ketoglutarate as a substrate, per minute at room temperature in 25 mM Tris-HCl, pH 7.5, 150 mM sodium chloride, and 5 mM MgCl<sub>2</sub>.

### Images



Lane 1: MW Markers  
Lane 2: IDH1 R123H (5 µg)  
Lane 3: IDH1 R123H (2.5 µg)  
Lane 4: IDH1 R123H (1.25 µg)

Representative gel image shown; actual purity may vary between each batch.

WARNING  
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA  
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY  
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/22/2016

CAYMAN CHEMICAL  
1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA  
PHONE: [800] 364-9897  
[734] 971-3335  
FAX: [734] 971-3640  
CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM

# PRODUCT INFORMATION



## Description

---

Isocitrate dehydrogenases (IDHs) are nicotinamide adenine dinucleotide (NAD<sup>+</sup>) and NAD phosphate (NADP<sup>+</sup>)-dependent enzymes that catalyze the third step of the tricarboxylic acid cycle. IDHs catalyze oxidative decarboxylation of isocitrate producing  $\alpha$ -ketoglutarate ( $\alpha$ -KG) and carbon dioxide. IDH1 (cytosolic) and IDH2 (mitochondrial) are NADP<sup>+</sup>-dependent enzymes that catalyze reversible reactions. The IDH3 isoform, a NAD<sup>+</sup>-dependent multisubunit enzyme, is irreversible and allosterically regulated by a variety of positive (calcium, ADP, and citrate) and negative (adenosine triphosphate, NADH, and NADPH) effectors.<sup>1</sup> IDH1 and IDH2 are mutated in >70% of lower grade gliomas.<sup>2</sup> The most common IDH mutation, Arg132His, imparts new gain of function catalytic activity leading to the NADPH-dependent conversion of  $\alpha$ -KG to 2-hydroxyglutarate.<sup>3,4</sup> Astrocytes expressing IDH1 R132H mutant have been shown to produce markedly increased levels of the R-2-hydroxyglutarate enantiomer, leading to transformation of cells through the hypoxia-inducible factor prolyl 4-hydroxylase, EGLN.<sup>5</sup>

## References

---

1. Raimundo, N., Baysal, B.E., and Shadel, G.S. Revisiting the TCA cycle: Signaling to tumor formation. *Trends Mol. Med.* **17(11)**, 641-649 (2011).
2. Turcan, S., Rohle, D., Goenka, A., *et al.* IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. *Nature* **483(7390)**, 479-483 (2012).
3. Reitman, Z.J. and Yan, H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: Alterations at a crossroads of cellular metabolism. *J. Natl. Cancer Inst.* **102(13)**, 932-941 (2010).
4. Dang, L., White, D.W., Gross, S., *et al.* Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature* **462(7274)**, (2009).
5. Koivunen, P., Lee, S., Duncan, C.G., *et al.* Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. *Nature* 1-7 (2012).

CAYMAN CHEMICAL  
1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA  
PHONE: [800] 364-9897  
[734] 971-3335  
FAX: [734] 971-3640  
CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM